
Er is geen geloofwaardig bewijs dat Sam Altman, sinds 2019 CEO van OpenAI, metformine neemt.
Deze bewering ontbeert substantiering in openbare verslagen, gezondheidsmededelingen of geverifieerde rapportage.
Altmans gezondheidsinformatie blijft privé.
Altman's documented activities center on OpenAI's product roadmap. Recent initiatives include OpenAI Dots, his unveiled ChatGPT AI personal agent, alongside the 2026 DevDay announcements. His tracked signals show 94 connections to Artificial Intelligence developments.
Health rumors about prominent figures often circulate online without verification. Without direct statements from Altman or credible medical sources, claims about his medications should be treated as unsubstantiated speculation rather than fact.